Benefits of early rhythm control of atrial fibrillation.

[1]  M. Haïssaguerre,et al.  The use of smartwatch electrocardiogram beyond arrhythmia detection. , 2023, Trends in cardiovascular medicine.

[2]  P. Kirchhof,et al.  Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial , 2023, The Lancet Neurology.

[3]  A. Verma,et al.  Progression of Atrial Fibrillation after Cryoablation or Drug Therapy. , 2022, The New England journal of medicine.

[4]  I. V. Van Gelder,et al.  Searching for atrial fibrillation: looking harder, looking longer, and in increasingly sophisticated ways. An EHRA position paper'. , 2022, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[5]  H. Crijns,et al.  Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial , 2022, European heart journal.

[6]  G. Breithardt,et al.  Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden , 2022, Circulation.

[7]  U. Schotten,et al.  Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference , 2022, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[8]  G. Breithardt,et al.  Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm Control Therapy. , 2022, Journal of the American College of Cardiology.

[9]  H. Crijns,et al.  The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation: JACC State-of-the-Art Review. , 2022, Journal of the American College of Cardiology.

[10]  L. Eckardt,et al.  Machine learning in the detection and management of atrial fibrillation , 2022, Clinical Research in Cardiology.

[11]  L. Eckardt,et al.  Evidence-based treatment of atrial fibrillation around the globe: comparison of the latest ESC, AHA/ACC/HRS, and CCS guidelines on the management of atrial fibrillation. , 2022, Reviews in cardiovascular medicine.

[12]  OUP accepted manuscript , 2022, Europace.

[13]  D. Mark,et al.  Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial , 2021, Circulation.

[14]  G. Breithardt,et al.  Corrigendum to: Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST-AFNET 4 trial , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[15]  H. Pak,et al.  Comparative Effectiveness of Early Rhythm Control Versus Rate Control for Cardiovascular Outcomes in Patients With Atrial Fibrillation , 2021, Journal of the American Heart Association.

[16]  H. Crijns,et al.  Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[17]  G. Breithardt,et al.  Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial , 2021, European heart journal.

[18]  G. Lip,et al.  Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry , 2021, Clinical Research in Cardiology.

[19]  G. Breithardt,et al.  Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure , 2021, Circulation.

[20]  G. Lip,et al.  Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study , 2021, BMJ.

[21]  S. Knecht,et al.  Quality of life and healthcare utilisation improvements after atrial fibrillation ablation , 2021, Heart.

[22]  D. Packer,et al.  Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation , 2021, Europace.

[23]  G. Breithardt,et al.  Early Rhythm Control in Atrial Fibrillation. Reply. , 2021, The New England journal of medicine.

[24]  A. Camm,et al.  Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[25]  K. Kuck,et al.  Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST) , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[26]  L. Eckardt,et al.  Role of the rabbit whole-heart model for electrophysiologic safety pharmacology of non-cardiovascular drugs. , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[27]  C. Morillo,et al.  Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. , 2020, The New England journal of medicine.

[28]  M. Shao,et al.  Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation. , 2020, The New England journal of medicine.

[29]  G. Breithardt,et al.  Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. , 2020, The New England journal of medicine.

[30]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[31]  J. Brachmann,et al.  Impact of Left Ventricular Function and Heart Failure Symptoms on Outcomes Post Ablation of Atrial Fibrillation in Heart Failure , 2020, Circulation. Arrhythmia and electrophysiology.

[32]  G. Hindricks,et al.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[33]  George A. Johnson,et al.  Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial. , 2020, Journal of the American College of Cardiology.

[34]  L. Di Biase,et al.  Impact of atrial fibrillation catheter ablation on mortality, stroke, and heart failure hospitalizations: A meta‐analysis , 2020, Journal of cardiovascular electrophysiology.

[35]  P. Kirchhof,et al.  Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation , 2019, European heart journal.

[36]  J. Tournoy,et al.  Clinical Outcomes of Rate vs Rhythm Control for Atrial Fibrillation in Older People: A Systematic Review and Meta-Analysis , 2019, Drugs & Aging.

[37]  J. Brachmann,et al.  Outcomes of cryoballoon or radiofrequency ablation in symptomatic paroxysmal or persistent atrial fibrillation , 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[38]  G. Hindricks,et al.  Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial , 2019, JAMA.

[39]  K. Anstrom,et al.  Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial , 2019, JAMA.

[40]  Pekka Raatikainen,et al.  Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation: The CAPTAF Randomized Clinical Trial , 2019, JAMA.

[41]  J. Brachmann,et al.  Long-term symptom improvement and patient satisfaction after AV-node ablation vs. pulmonary vein isolation for symptomatic atrial fibrillation: results from the German Ablation Registry , 2018, Clinical Research in Cardiology.

[42]  É. Marijon,et al.  Association of catheter ablation for atrial fibrillation with mortality and stroke: A systematic review and meta-analysis. , 2018, International journal of cardiology.

[43]  L. Jordaens,et al.  Catheter Ablation for Atrial Fibrillation with Heart Failure , 2018, The New England journal of medicine.

[44]  Charles R Kerr,et al.  Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation. , 2017, Heart rhythm.

[45]  J. Brachmann,et al.  Sex-related outcome of atrial fibrillation ablation: Insights from the German Ablation Registry. , 2016, Heart rhythm.

[46]  Dhanunjaya R. Lakkireddy,et al.  Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial , 2016, Circulation.

[47]  S. Pocock,et al.  Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. , 2016, The New England journal of medicine.

[48]  L. Eckardt,et al.  Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms , 2016, Nature Reviews Cardiology.

[49]  Á. Avezum,et al.  Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. , 2015, European heart journal.

[50]  Niels Voigt,et al.  Cellular and Molecular Electrophysiology of Atrial Fibrillation Initiation, Maintenance, and Progression , 2014, Circulation research.

[51]  L. Eckardt,et al.  Supraventricular Premature Beats and Short Atrial Runs Predict Atrial Fibrillation in Continuously Monitored Patients With Cryptogenic Stroke , 2014, Stroke.

[52]  J. Healey,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. , 2014, JAMA.

[53]  Lluís Mont,et al.  Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study) , 2013, European heart journal.

[54]  P. Kirchhof,et al.  Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF) , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[55]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[56]  B. Gersh,et al.  Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT‐AF Registry , 2013, Journal of the American Heart Association.

[57]  J. Ruskin,et al.  Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. , 2013, Journal of the American College of Cardiology.

[58]  J. Hartikainen,et al.  Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. , 2012, The New England journal of medicine.

[59]  Ashok J. Shah,et al.  Improved outcome following restoration of sinus rhythm prior to catheter ablation of persistent atrial fibrillation: a comparative multicenter study. , 2012, Heart rhythm.

[60]  G. Breithardt,et al.  A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase‐III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing‐induced heart failure , 2011, European journal of heart failure.

[61]  P. Milberg,et al.  Randomized study comparing duty-cycled bipolar and unipolar radiofrequency with point-by-point ablation in pulmonary vein isolation. , 2011, Heart rhythm.

[62]  Burr Hall,et al.  Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. , 2010, JAMA.

[63]  S. Connolly,et al.  Effect of dronedarone on cardiovascular events in atrial fibrillation. , 2009, The New England journal of medicine.

[64]  Stephan Willems,et al.  Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. , 2009, European heart journal.

[65]  M. Hirai,et al.  Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[66]  F. Sacher,et al.  Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation: The A4 Study , 2008, Circulation.

[67]  A. Camm,et al.  Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure , 2009 .

[68]  Mandeep Bhargava,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. , 2005, JAMA.

[69]  J. Dimarco,et al.  Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. , 2005, American heart journal.

[70]  G. Breithardt,et al.  Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of LQT3. , 2005, Cardiovascular research.

[71]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .

[72]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[73]  S. Hohnloser,et al.  Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial , 2000, The Lancet.

[74]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[75]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.